Merck & Co., Inc. (BCBA:MRK)
Argentina · Delayed Price · Currency is ARS | Market Cap | 531.49T +74.1% |
| Revenue (ttm) | 98.62T +4.6% |
| Net Income | 4.70T -80.7% |
| EPS | 1,885.72 -80.4% |
| Shares Out | n/a |
| PE Ratio | 113.06 |
| Forward PE | 16.86 |
| Dividend | 630.95 (1.38%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 5,665 |
| Open | 47,280 |
| Previous Close | 46,940 |
| Day's Range | 45,580 - 47,280 |
| 52-Week Range | 23,300 - 50,125 |
| Beta | 0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
The Federal Trade Commission said Martin Shkreli is still trading pharmaceutical stocks. The FTC said the "Pharma Bro" continues to do this despite a lifetime ban.
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.
Merck announces Diaz to join Board of Directors
Merck (MRK) & Co. announced that Paul Diaz, managing partner at Cressey & Company, will join the Company’s Board of Directors effective Nov. 1, 2026. He will stand for election…
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
RAHWAY, N.J.--(BUSINESS WIRE)--Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors.
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be...
Merck price target lowered to $145 from $150 at RBC Capital
RBC Capital analyst Trung Huynh lowered the firm’s price target on Merck (MRK) to $145 from $150 and keeps a Sector Perform rating on the shares. The firm is reducing…
Merck price target raised to $145 from $125 at Citi
Citi raised the firm’s price target on Merck (MRK) to $145 from $125 and keeps a Neutral rating on the shares. The firm says the biopharma backdrop “remains constructive” into…
Merck announces one-year results from Phase 2b/3 Brunello trial
Merck (MRK) announced the first presentation of one-year results from the pivotal Phase 2b/3 Brunello trial evaluating remigromig, an investigational, potentially first-in-class tetravalent, tri-speci...
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase ...
Merck price target lowered to $163 from $166 at BofA
BofA lowered the firm’s price target on Merck (MRK) to $163 from $166 and keeps a Buy rating on the shares as part of the firm’s Q3 EPS preview for…
Merck price target raised to $145 from $120 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Merck (MRK) to $145 from $120 and keeps a Neutral rating on the shares. Increasing expectations for a 2027…
Merck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock.
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.
Halozyme wins court order to block Merck's injected Keytruda in select European markets
Biopharma company Halozyme said on Wednesday that a Dutch patent court ruled in its favor against Merck , ordering the drugmaker to halt the manufacture and sale of injectable Keytruda in eight Euro...
Merck price target lowered to $177 from $179 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Merck (MRK) to $177 from $179 and keeps an Overweight rating on the shares. The firm adjusted its models for its biopharma…
Tempus AI announces multi-year collaboration with Moderna, Merck
Tempus (TEM) announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy bein...
Halozyme announces Dutch court of the Hague found Merck infringed patents
Halozyme Therapeutics (HALO) announced that the specialized Dutch patent court of the Hague has found Merck (MRK) to be infringing one of its MDASE patents, EP 2,797,622 and ordered Merck’s…
Merck price target raised to $165 from $150 at JPMorgan
JPMorgan raised the firm’s price target on Merck (MRK) to $165 from $150 and keeps an Overweight rating on the shares ahead of the Q3 report on October 29. The…
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29.
Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright
After Merck (MRK) presented Phase 2b data for tulisokibart in moderate-to-severe hidradenitis suppurativa at the EADV Congress and reported that it met the primary endpoint and will be advancing into…
Merck says experimental skin disease drug meets main goal in mid-stage study
Merck said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps,...
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b mul...
US drugmakers turn to China for licensing deals
Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-develop...
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
Merck said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment.
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into ...